C&L: Hedegaard takes helm at Bavarian Nordic

Bavarian Nordic said Anders Hedegaard will assume the position of president and CEO of the group on August 1. Peter Wulff will transfer to the position of executive vice president of business development.

Xechem International announced that Dr. Robert Swift, a member of Xechem's board of directors, has been appointed by the board of directors to take on the role of chairman and CEO/President on an interim basis, replacing Dr. Ramesh Pandey, who will continue to serve on the company's board of directors.

Anacor Pharmaceuticals has named Christine Gray-Smith as its senior vice president and CFO.

Biomira announced the appointment of Gary Christianson to the newly created position of COO.

Halozyme Therapeutics announced that Walter Bee, PhD has been named vice president, preclinical development.

CV Therapeutics announced the appointment of Lewis Stuart as senior vice president, commercial operations.

Nabi Biopharmaceuticals announced that it has appointed Dr. Matthew W. Kalnik to the role of vice president, business development and project management.

WuXi PharmaTech has named Dr. Lijie Fu as the company's VP of operation and head of operation, SuZhou PharmaTech.

Keryx Biopharmaceuticals announced that William P. Kane has joined the company as vice president, commercial operations.

Jerald C. Sadoff, MD, has joined the NanoBio Scientific Advisory Board.

Oxford Gene Technology has named Dr. Tim Cook to the OGT board.

BrainStorm Cell Therapeutics has elected Moshe Lion to the company's board of directors.

Bioenvision said that Andrew N. Schiff and Steven A. Elms have resigned from the drug maker's board.

Mersana Therapeutics has named Nicholas G. Bacopoulos, Ph.D. to its board of directors.

Resverlogix has named Dr. Roger Newton to its board of directors.

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.